Renaissance Technologies LLC Purchases 82,120 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Renaissance Technologies LLC grew its position in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 14.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 646,920 shares of the company’s stock after purchasing an additional 82,120 shares during the quarter. Renaissance Technologies LLC owned approximately 1.29% of Immunocore worth $21,924,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. NEOS Investment Management LLC bought a new position in shares of Immunocore during the 4th quarter valued at about $262,000. Tidal Investments LLC bought a new position in shares of Immunocore during the 1st quarter valued at about $423,000. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 69.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after purchasing an additional 2,721 shares during the last quarter. Nan Fung Group Holdings Ltd bought a new position in shares of Immunocore during the 1st quarter valued at about $439,000. Finally, DNB Asset Management AS increased its position in shares of Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after purchasing an additional 1,868 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Trading Down 3.0 %

NASDAQ IMCR opened at $33.18 on Friday. Immunocore Holdings plc has a fifty-two week low of $32.37 and a fifty-two week high of $76.98. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17. The stock has a 50 day simple moving average of $36.84 and a two-hundred day simple moving average of $46.50. The stock has a market cap of $1.66 billion, a P/E ratio of -27.20 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.25. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The business had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. During the same quarter last year, the business posted ($0.37) EPS. The business’s revenue was up 26.2% on a year-over-year basis. On average, analysts forecast that Immunocore Holdings plc will post -1.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IMCR. Oppenheimer reiterated an “outperform” rating and set a $89.00 price objective (up from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Needham & Company LLC dropped their target price on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. dropped their target price on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.40.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.